Affimed NV
AFMD0.181USD
-0.098-34.95%
收盘 08/04, 16:00（美东）报价延迟15分钟
2.98M总市值
亏损市盈率 TTM
关于 Affimed NV 公司
Affimed NV 是一家临床阶段的生物制药公司，专注于发现和开发癌症免疫疗法。该公司的候选产品是在免疫肿瘤学领域开发的，免疫肿瘤学代表了一种癌症研究方法，旨在利用人体自身的免疫系统对抗肿瘤细胞。其产品线包括 AFM13、AFM13 + 过继性 NK 细胞、AFM13 + 抗 PD-1、AMF24、AMF26、AMF28 和 AMF32。该公司正在招募患者参加 AFM13 的注册导向研究，用于治疗 CD30 阳性复发/难治性外周 T 细胞淋巴瘤，以及 AFM24 的 1/2a 期剂量递增/扩展研究，用于治疗晚期 EGFR 表达实体瘤。其临床前候选产品包括用于治疗多发性骨髓瘤的 AMF26，以及用于治疗多种肿瘤靶点的 AMF28 和 AMF32。此外，该公司还与 Genentech 合作开发和商业化用于治疗多种癌症的某些候选产品。
公司简介
公司代码AFMD
公司名称Affimed NV
上市日期Sep 12, 2014
CEOMr. Shawn M. Leland
员工数量76
证券类型Ordinary Share
年结日Sep 12
公司地址Im Neuenheimer Feld 582
城市HEIDELBERG
上市交易所Berne Stock Exchange
国家Germany
邮编69120
电话49621560030
网址https://www.affimed.com/
公司代码AFMD
上市日期Sep 12, 2014
CEOMr. Shawn M. Leland
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Wolfgang Fischer, Ph.D.
Dr. Wolfgang Fischer, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
145.54K
+34.45%
Ms. Denise Mueller
Ms. Denise Mueller
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
89.88K
+65.92%
Dr. Andreas Harstrick, M.D.
Dr. Andreas Harstrick, M.D.
Chief Medical Officer, Member of the Management Board
Chief Medical Officer, Member of the Management Board
76.04K
+88.54%
Dr. Mathieu Simon
Dr. Mathieu Simon
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
15.00K
+36.36%
Mr. Harry Welten
Mr. Harry Welten
Consulting Chief Financial Officer, Member of the Management Board
Consulting Chief Financial Officer, Member of the Management Board
15.00K
+36.36%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
14.00K
+16.67%
Ms. Uta Kemmerich-Keil
Ms. Uta Kemmerich-Keil
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
11.00K
+83.33%
Mr. Shawn M. Leland
Mr. Shawn M. Leland
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Bernhard R. M. Ehmer
Dr. Bernhard R. M. Ehmer
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Thomas Hecht, M.D.
Dr. Thomas Hecht, M.D.
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Wolfgang Fischer, Ph.D.
Dr. Wolfgang Fischer, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
145.54K
+34.45%
Ms. Denise Mueller
Ms. Denise Mueller
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
89.88K
+65.92%
Dr. Andreas Harstrick, M.D.
Dr. Andreas Harstrick, M.D.
Chief Medical Officer, Member of the Management Board
Chief Medical Officer, Member of the Management Board
76.04K
+88.54%
Dr. Mathieu Simon
Dr. Mathieu Simon
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
15.00K
+36.36%
Mr. Harry Welten
Mr. Harry Welten
Consulting Chief Financial Officer, Member of the Management Board
Consulting Chief Financial Officer, Member of the Management Board
15.00K
+36.36%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
14.00K
+16.67%
收入明细
单位: EUR更新时间: 7月6日 周日
单位: EUR更新时间: 7月6日 周日
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务EUR
名称
营收
占比
Collaboration revenue
155.00K
0.00%
Service revenue
0.00
0.00%
地区EUR
名称
营收
占比
United States
155.00K
100.00%
Germany
0.00
0.00%
业务
地区
业务EUR
名称
营收
占比
Collaboration revenue
155.00K
0.00%
Service revenue
0.00
0.00%
股东统计
更新时间: 7月25日 周五
更新时间: 7月25日 周五
持股股东
股东类型
持股股东
持股股东
占比
Gilde Healthcare Partners B.V.
5.34%
683 Capital Management LLC
4.30%
New Enterprise Associates (NEA)
2.91%
Point72 Asset Management, L.P.
2.25%
Hoess (Adi Ph.D.)
2.10%
Other
83.11%
持股股东
持股股东
占比
Gilde Healthcare Partners B.V.
5.34%
683 Capital Management LLC
4.30%
New Enterprise Associates (NEA)
2.91%
Point72 Asset Management, L.P.
2.25%
Hoess (Adi Ph.D.)
2.10%
Other
83.11%
股东类型
持股股东
占比
Venture Capital
8.49%
Hedge Fund
7.52%
Individual Investor
6.01%
Investment Advisor/Hedge Fund
1.57%
Investment Advisor
1.14%
Research Firm
0.79%
Other
74.48%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
144
3.89M
25.52%
-2.82M
2025Q1
194
5.44M
35.72%
-1.40M
2024Q4
223
4.37M
28.70%
-3.86M
2024Q3
244
6.36M
129.59%
-2.88M
2024Q2
256
6.34M
129.44%
-2.70M
2024Q1
265
6.05M
127.57%
-3.49M
2023Q4
282
6.20M
128.84%
-3.49M
2023Q3
294
6.99M
46.94%
-2.84M
2023Q2
315
7.55M
50.71%
-3.53M
2023Q1
317
8.81M
59.15%
-2.41M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Gilde Healthcare Partners B.V.
812.50K
5.34%
+812.50K
--
Mar 15, 2024
683 Capital Management LLC
654.60K
4.3%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
442.65K
2.91%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
342.86K
2.25%
--
--
Mar 31, 2025
Hoess (Adi Ph.D.)
319.68K
2.1%
+66.08K
+26.06%
Mar 15, 2024
Tang Capital Management, LLC
148.31K
0.97%
--
--
Mar 31, 2025
Fischer (Wolfgang)
145.54K
0.96%
+37.29K
+34.45%
Mar 15, 2024
The Vanguard Group, Inc.
129.56K
0.85%
--
--
Mar 31, 2025
Intellectus Partners, LLC
126.41K
0.83%
--
--
Mar 31, 2025
Marshall Wace LLP
111.64K
0.73%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Fidelity Enhanced Small Cap ETF
0%
SPDR S&P International Small Cap ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Invesco Nasdaq Biotechnology ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
iShares Biotechnology ETF
0%
Fidelity Enhanced Small Cap ETF
占比0%
SPDR S&P International Small Cap ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
SPDR Portfolio Developed World ex-US ETF
占比0%
iShares Biotechnology ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
公告日期
类型
比率
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
